We report a case of a premature very low birth weight infant who presented shortly after birth with idiopathic central diabetes insipidus that persisted beyond the neonatal period and has been successfully managed with intranasal 1-desamino-8-D-arginine vasopressin. Although this condition is rare in neonates, early recognition, evaluation, and therapy may prevent more severe morbidity. Long-term successful management resulting in normal growth and development during infancy can be achieved with intranasal 1-desamino-8-D-arginine vasopressin therapy.
Chronic idiopathic central diabetes insipidus (DI) is an uncommon disorder in children that is rarely recognized in the neonatal period. Although the etiology and treatment have been well described in the older pediatric population, the causes and management of central DI in neonates, especially in premature infants, are not as well understood. Previous cases described in the neonatal literature involve transient central DI secondary to a known etiology such as severe intraventricular hemorrhage, sepsis, disseminated intravascular coagulopathy, and/or congenital central nervous system malformations presenting with evidence of hypothalamic-pituitary dysfunction. We report a case of a premature very low birth weight infant who presented shortly after birth with idiopathic central DI whose symptoms persisted beyond the neonatal period; this infant was successfully managed with intranasal 1-desamino-8-D-arginine vasopressin (dDAVP).
CASE REPORT
An outborn 660-gm African American infant boy was born by vaginal delivery at a gestational age of 23 weeks and 6 days to a 25-year-old gravida 2, para 0 woman after a pregnancy complicated by premature labor. The pregnancy was otherwise unevent-ful with good prenatal care. Immediately after birth, the patient was intubated for respiratory distress and received prophylactic surfactant. Apgars were 1, 6, and 8 at 1, 5, and 10 minutes, respectively. After stabilization, the patient was transported to our institution for continued management of his extreme prematurity. His initial hospital course was complicated by respiratory distress requiring ventilator support for the first 30 days of life. A patent ductus arteriosus at 1 week of age was medically closed with indomethacin therapy. After extubation, continuous oxygen supplementation through a nasal cannula was necessary for the next 2 months secondary to residual chronic lung disease. Ampicillin and cefotaxime were continued for the first 7 days of life until all cultures including cerebrospinal fluid were negative. Cranial ultrasound at 72 hours of life noted a right grade II and a left grade I intraventricular hemorrhage that was unchanged on subsequent scans and completely resolved without residual ventriculomegaly or cystic periventricular injury by 2 months of age. The patient also developed bilateral stage III retinopathy of prematurity that regressed after treatment with laser surgery.
On day 21 of life, significant hypernatremia and polyuria of uncertain etiology acutely developed. Serum sodium increased to 158 meq/dl from a baseline of 140 meq/dl (normal range 135 to 148 at our institution) and urine output increased from 2 to 3 ml/kg per hour to 5 to 6 ml/kg per hour. Over the next several days, hypernatremia persisted (serum sodium 156 to 164 meq/dl) and urine output remained elevated at 4 to 9 ml/kg per hour despite the removal of all sodium from parenteral nutrition and significantly increasing free water intake. The infant was also receiving enteral feeds with human milk during this period, and the sodium content of the maternal expressed human milk was measured and noted to be 3 meq/dl (normal 2 to 6 meq/dl). Further evaluations done at this time included urine lytes (sodium at Ͻ10 meq/dl), specific gravity (1.010), and osmolarity (178 mosM/liter; serum osmolarity 331 mosM/liter). Serum chemistries including blood urea nitrogen, creatinine, and bicarbonate were normal without evidence of renal dysfunction or metabolic acidosis. Thyroid function, serum cortisol, urine-free cortisol, and a renal/bladder ultrasound were also normal, and a 24-hour urine collection showed normal creatinine clearance. The diagnosis of idiopathic central DI was made.
Despite conservative management, clinical symptoms persisted over the next 4 weeks, and treatment with continuous intravenous desmopressin was initiated at a dose of 1.5 mU/kg per hour. Over the
next several weeks, the desmopressin infusion was titrated to maintain serum sodiums and urine output within a normal range. The patient responded well to this therapy, with serum sodium decreasing to the mid 140 range and urine output decreasing to 3 ml/kg per hour. During this time, he manifested good weight gain on full enteral feeds of fortified human milk at 150 ml/kg per day. On day 105 of life, therapy was converted to intranasal dDAVP at 0.5 g/day. The dDAVP was concentrated at 100 g/10 ml and dosed as 0.025 ml every 12 hours. Over the next month, the dose was increased to 0.05 ml twice a day (1.0 g/day). Serum sodiums remained stable at 141 to 148 meq/dl, with serum osmolarity at 289 to 291 U and urine output at 2 to 3 ml/kg per day. Therapy was well tolerated without any noted adverse events. At 4 months of age, the patient was sent home on intranasal dDAVP following a relatively uneventful remaining hospital course. A magnetic resonance imaging scan performed shortly after discharge was within normal limits and without evidence of hypothalamicpituitary abnormalities. At 24 months of age, he is continuing to develop normally. Attempts to wean him off therapy at this time were unsuccessful, and he remains on intranasal dDAVP at a dose of 1.0 g/day divided every 12 hours.
DISCUSSION
Although the etiology and treatment of central DI has been described previously in several case series in children, [1] [2] [3] it remains a relatively rare disorder in the neonatal population, specifically in very low birth weight premature infants. To our knowledge, our case is the youngest infant reported in the literature presenting in the neonatal period with persistent, idiopathic central DI that was successfully managed with intranasal dDAVP.
In 1986, Greger et al. 1 reported a series involving 73 children with central DI. They found that almost 50% of cases were due to intracranial tumors, 14% were due to intracranial defects, and 11% were due to severe central nervous system infections. Only 9 of 73 patients in their study (12.4%) were classified as idiopathic. The exact ages of their patients were not described, but the average age in each category was reported as 0.2 to 8.7 years of age. In 1994, Wang et al. 2 published a series on 35 pediatric patients (aged 3 weeks to 19 years) with central DI in which over half of the cases (19 of 35) were secondary to intracranial tumor; only 5 of 35 were classified as idiopathic. They also noted that 31 of 35 of their patients had other coexisting endocrinopathies. Both of these studies note intracranial tumors as the most common etiology of central DI in infants and children, with idiopathic causes accounting for Ͻ15% of cases.
In the neonatal literature, there are several previous case reports of infants presenting with DI in the first month of life. Giacoia et al. 4 described a case in which a 1880-gm infant girl born at 31 weeks' gestation developed transient idiopathic central DI on day 7 of life. The infant was treated initially with intramuscular aqueous pitressin followed by intranasal dDAVP dosed at 1 to 2 g/day divided every 12 hours. The dose of dDAVP was able to be progressively weaned as symptoms eventually resolved by 3 months of age. Yarber and Wood 5 reported a 1040-gm infant boy delivered at 28 weeks' gestation who developed unexplained hypernatremia and polyuria within the first week of life and was subsequently diagnosed with idiopathic central DI. He was initially treated with subcutaneous dDAVP. Therapy was converted to oral dDAVP for discharge home. Their patient was also noted to have hypothalamic-pituitary dysfunction with decreased serum levels of cortisol and adrenocorticotropin hormone requiring replacement hydrocortisone therapy. Growth hormone levels were also noted to be borderline low; however, therapy was not considered to be necessary. The duration of this patient's symptoms and therapy for central DI were not reported. Both transient and permanent cases of central DI have also been reported in neonates secondary to intraventricular hemorrhage, group B streptococcal meningitis, septo-optic dysplasia, Listeria monocytogenes sepsis, congenital cytomegalovirus, mid-line intracranial defect, and following surgical resection of a suprasellar mass. 6 -12 Our patient had a normal magnetic resonance imaging scan that did not show any abnormalities of the hypothalamic-pituitary axis. When considering other etiologies, our patient did have bilateral intraventricular hemorrhages; however, these were mild, occurring within the first week of life and subsequently resolving on follow-up imaging. He did not have any documented meningitis or other central nervous system infections during his hospital course. Urine cytomegalovirus culture was also negative. There was no evidence of a coexisting endocrinopathy. Thyroid function as well as serum and urine-free cortisol levels were normal. Weight and height growth velocities after treatment with intranasal vasopressin were appropriate for age, indicating apparent normal growth hormone levels; however, a specific evaluation was not done.
In a review of the literature, treatment of cranial DI was initially conducted by administering intramuscular pitressin in tannate oil. 13 Although somewhat successful in treating polyuria and hypernatremia, this method of treatment requires repeat intramuscular injections and therefore is not suitable for long-term management. Lysine vasopressin is another synthetic peptide that has been used in both intravenous and intranasal forms; however, it is a relatively shortacting agent that requires between 3 and 8 doses per 24 hours to maintain its effect. Pitressin and vasopressin also act on both the V 1 and V 2 receptors, causing them to have more pronounced pressor effects as well and resulting in potentially significant gastrointestinal side effects. 14 In the late 1960s, the vasopressin analog desmopressin was developed. It is available in oral, intravenous, and intranasal forms and has become the preferred treatment for patients with central DI. It appears to act almost exclusively on the V 2 receptor and has minimal pressor effects. It does not appear to interfere with endogenous antidiuretic hormone production, and patients rarely develop tolerance to its effects even after long-term use. Although its use intranasally in children is well documented, there is some controversy as to the best method of delivery in neonates and infants for long-term therapy. Paulsen-Fjellestad et al. 15 commented that nasal absorption is irregular in infants, leading to hypernatremia and wide fluctua-tions in antidiuretic effects. Stick et al. 11 reported the use of intranasal dDAVP therapy in a term infant with a cleft lip and palate; however, therapy was converted to oral dDAVP secondary to a significant variability in urine output and weight gain.
Previous studies have reported successful treatment of central DI in neonates with intranasal dDAVP given at doses ranging from 0.5 to 2 g/day. 4 Giacoia et al. 4 recommended diluting the dDAVP solution by 1/10 in saline for doses of Ͻ2.5 g. We started our patient on 0.5 g/day divided every 12 hours because he weighed only 1270 gm at the onset of therapy. He ultimately required an increase to 1 g/day divided every 12 hours to keep his serum sodium and urine output within normal limits, and was subsequently discharged from the hospital on this dose.
In summary, we have presented the case of a very low birth weight premature infant with onset of idiopathic central DI in the first several weeks of life who was successfully managed with intranasal dDAVP. The diagnosis of idiopathic central DI should be considered in the neonate, including extremely premature infants, with onset of unexplained hypernatremia and polyuria. Families should be counseled that these symptoms may not be transient and may require long-term treatment. We recommend that intravenous desmopressin initially be administered at a dose of 1 to 3 mU/kg per hour once the diagnosis of central DI has been established. Once a clinical response has been established, the patient can be transitioned to intranasal dDAVP at a dose of 0.5 g/day divided every 12 hours. This dose may then be subsequently titrated to achieve the desired clinical effect.
